The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• FornerALlovetJMBruixJHepatocellular carcinomaLancet201237998221245125522353262
   PubMed Web of Science ®Google Scholar
• RazaASoodGKHepatocellular carcinoma review: current treatment, and evidence-based medicineWorld J Gastroenterol201420154115412724764650
   PubMed Web of Science ®Google Scholar
• ZhangJZhouZGHuangZXProspective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinomaChin J Cancer20163512526956022
   PubMedGoogle Scholar
• BruixJShermanMPractice Guidelines Committee, American Association for the Study of Liver DiseasesManagement of hepatocellular carcinomaHepatology20054251208123616250051
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver, European Organisation for Research and Treatment of CancerEASL-EORTC clinical practice guidelines: management of hepatocellular carcinomaJ Hepatol201256490894322424438
   PubMed Web of Science ®Google Scholar
• PalmerDHSorafenib in advanced hepatocellular carcinomaN Engl J Med20083592324982499
   PubMedGoogle Scholar
• ParkJWChenMColomboMGlobal patterns of hepatocellular carcinoma management from diagnosis to death: the bridge studyLiver Int20153592155216625752327
   PubMed Web of Science ®Google Scholar
• LlovetJMBruixJSystematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survivalHepatology200337242944212540794
   PubMed Web of Science ®Google Scholar
• BruixJShermanMAmerican Association for the Study of Liver DiseasesManagement of hepatocellular carcinoma: an updateHepatology20115331020102221374666
   PubMed Web of Science ®Google Scholar
• LlovetJMBurroughsABruixJHepatocellular carcinomaLancet200336293991907191714667750
   PubMed Web of Science ®Google Scholar
• BalkwillFMantovaniAInflammation and cancer: back to Virchow?Lancet2001357925553954511229684
   PubMed Web of Science ®Google Scholar
• FerreriAJMIllerhausGZuccaECavalliFInternational Extranodal Lymphoma Study GroupFlows and flaws in primary central nervous system lymphomaNat Rev Clin Oncol20107812
   Web of Science ®Google Scholar
• TempletonAJKnoxJJLinXChange in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacyEur Urol201670235836426924770
   PubMed Web of Science ®Google Scholar
• TempletonAJMcNamaraMGŠerugaBPrognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysisJ Natl Cancer Inst20141066dju12424875653
   PubMedGoogle Scholar
• DengMMaXLiangXZhuCWangMAre pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?Oncotarget2017823372003720728380461
   PubMedGoogle Scholar
• RossiSBassoMStrippoliAAre markers of systemic inflammation good prognostic indicators in colorectal cancer?Clin Colorectal Cancer201716426427428412137
   PubMed Web of Science ®Google Scholar
• SongWTianCWangKZhangRJZouSBPreoperative platelet lymphocyte ratio as independent predictors of prognosis in pancreatic cancer: a systematic review and meta-analysisPLoS One2017126e017876228575033
   PubMed Web of Science ®Google Scholar
• ZhaoYSiGZhuFPrognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysisOncotarget2017814228542286228206965
   PubMedGoogle Scholar
• DongLBaiKCaoYHuangQLvLJiangYPrognostic value of pre-operative platelet to lymphocyte ratio in patients with resected primary hepatocellular carcinomaClin Lab201662112191219628164677
   PubMed Web of Science ®Google Scholar
• HeCBLinXJInflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101PLoS One2017123e017476928355305
   PubMed Web of Science ®Google Scholar
• YangTZhuJZhaoLLymphocyte to monocyte ratio and neutrophil to lymphocyte ratio are superior inflammation-based predictors of recurrence in patients with hepatocellular carcinoma after hepatic resectionJ Surg Oncol2017115671872828127774
   PubMed Web of Science ®Google Scholar
• BruixJShermanMLlovetJMClinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the LiverJ Hepatol200135342143011592607
   PubMed Web of Science ®Google Scholar
• LeeYHHsuCYHuangYHVascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impactJ Clin Gastroenterol201448873474124100755
   PubMed Web of Science ®Google Scholar
• WangDSLuoHYQiuMZComparison of the prognostic values of various inflammation based factors in patients with pancreatic cancerMed Oncol20122953092310022476808
   PubMed Web of Science ®Google Scholar
• ProctorMJMorrisonDSTalwarDAn inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome studyBr J Cancer2011104472673421266974
   PubMed Web of Science ®Google Scholar
• LuoJGuoRPLaiECTransarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative studyAnn Surg Oncol201118241342020839057
   PubMed Web of Science ®Google Scholar
• GalunDBogdanovicADjokic KovacJBulajicPLoncarZZuvelaMPreoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative-intent surgery for hepatocellular carcinoma: experience from a developing countryCancer Manag Res20181097798829765248
   PubMed Web of Science ®Google Scholar
• FlussRFaraggiDReiserBEstimation of the Youden index and its associated cutoff pointBiom J200547445847216161804
   PubMed Web of Science ®Google Scholar
• PedrazzaniCMantovaniGFernandesEAssessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancerSci Rep201771149428473700
   PubMedGoogle Scholar
• KitanoYYamashitaYIYamamuraKEffects of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios on survival in patients with extrahepatic cholangiocarcinomaAnticancer Res20173763229323728551669
   PubMed Web of Science ®Google Scholar
• CoussensLMWerbZInflammation and cancerNature2002420691786086712490959
   PubMed Web of Science ®Google Scholar
• MantovaniAAllavenaPSicaABalkwillFCancer-related inflammationNature2008454720343644418650914
   PubMed Web of Science ®Google Scholar
• GrivennikovSIGretenFRKarinMImmunity, inflammation, and cancerCell2010140688389920303878
   PubMed Web of Science ®Google Scholar
• Bard-ChapeauEANguyenATRustAGTransposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse modelNat Genet2014461243224316982
   PubMed Web of Science ®Google Scholar
• JiangDKSunJCaoGGenetic variants in Stat4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinomaNat Genet2013451727523242368
   PubMed Web of Science ®Google Scholar
• EndigJBuitrago-MolinaLEMarhenkeSDual role of the adaptive immune system in liver injury and hepatocellular carcinoma developmentCancer Cell201630230832327478039
   PubMed Web of Science ®Google Scholar
• MohsAKuttkatNReißingJFunctional role of CCL5/RAN-TES for HCC progression during chronic liver diseaseJ Hepatol201766474375328011329
   PubMed Web of Science ®Google Scholar
• WangYZhengCLiangBHepatocellular necrosis, apoptosis, and proliferation after transcatheter arterial embolization or chemo-embolization in a standardized rabbit modelJ Vasc Interv Radiol201122111606161221959058
   PubMed Web of Science ®Google Scholar
• ChaoYWuCYKuoCYCytokines are associated with postembolization fever and survival in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolizationHepatol Int20137388389226201926
   PubMed Web of Science ®Google Scholar
• McNallyMEMartinezAKhabiriHInflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolizationAnn Surg Oncol201320392392822965570
   PubMed Web of Science ®Google Scholar
• SiebenMHerzerKZeidlerMKilling of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia proteinWorld J Gastroenterol200814243819382818609705
   PubMed Web of Science ®Google Scholar
• LiYYuDCChenYA hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicinCancer Res200161176428643611522637
   PubMed Web of Science ®Google Scholar
• de VisserKEEichtenACoussensLMParadoxical roles of the immune system during cancer developmentNat Rev Cancer200661243716397525
   PubMed Web of Science ®Google Scholar
• JaiswalMLarussoNFBurgartLJGoresGJInflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanismCancer Res200060118419010646872
   PubMed Web of Science ®Google Scholar
• IshigamiSNatsugoeSTokudaKPrognostic value of intratumoral natural killer cells in gastric carcinomaCancer200088357758310649250
   PubMed Web of Science ®Google Scholar
• DannenbergAJSubbaramaiahKTargeting cyclooxygenase-2 in human neoplasia: rationale and promiseCancer Cell20034643143614706335
   PubMed Web of Science ®Google Scholar
• SchoppmannSFBirnerPStöcklJTumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesisAm J Pathol2002161394795612213723
   PubMed Web of Science ®Google Scholar
• LiuCHChangSHNarkoKOverexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic miceJ Biol Chem200127621185631856911278747
   PubMed Web of Science ®Google Scholar
• WiesnerTBuglSMayerFHartmannJTKoppHGDifferential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancerClin Exp Metastasis201027314114920182908
   PubMed Web of Science ®Google Scholar
• DunnGPOldLJSchreiberRDThe immunobiology of cancer immunosurveillance and immunoeditingImmunity200421213714815308095
   PubMed Web of Science ®Google Scholar
• StotzMPichlerMAbsengerGThe preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancerBr J Cancer2014110243544024357796
   PubMed Web of Science ®Google Scholar
• ZouWImmunosuppressive networks in the tumour environment and their therapeutic relevanceNat Rev Cancer20055426327415776005
   PubMed Web of Science ®Google Scholar
• ZhangNGuJYinLIncorporation of alpha-fetoprotein (AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER databaseOncotarget2016749813898140127835609
   PubMedGoogle Scholar
• LiZXueTQChenXYPredictive values of serum VEGF and CRP levels combined with contrast enhanced MRI in hepatocellular carcinoma patients after TACEAm J Cancer Res20166102375238527822426
   PubMed Web of Science ®Google Scholar
• WuSJLinYXYeHXiongXZLiFYChengNSPrognostic value of alkaline phosphatase, gamma-glutamyl transpeptidase and lactate dehydrogenase in hepatocellular carcinoma patients treated with liver resectionInt J Surg201636Pt A14315127793641
   PubMedGoogle Scholar
• RekikSGuyotEBhaisMThe CRP level and state score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolizationDig Liver Dis20164891088109227375209
   PubMedGoogle Scholar
• LiuCJiaBSZouBWNeutrophil-to-lymphocyte and aspartate-to-alanine aminotransferase ratios predict hepatocellular carcinoma prognosis after transarterial embolizationMedicine20179645e851229137051
   PubMed Web of Science ®Google Scholar
• TianXCLiuXLZengFRChenZWuDHPlatelet-to-lymphocyte ratio acts as an independent risk factor for patients with hepatitis B virus-related hepatocellular carcinoma who received transarterial chemoembolizationEur Rev Med Pharmacol Sci201620112302230927338055
   PubMed Web of Science ®Google Scholar